Bharati Vidyapeeth Deemed University, Pune, India.
B. J. Medical College & Sassoon Hospital, Pune, India.
BMC Pediatr. 2023 Mar 31;23(1):149. doi: 10.1186/s12887-023-03964-9.
Persistent pulmonary hypertension of the newborn (PPHN) is a common neonatal condition associated with significant morbidity and mortality. First-line diagnostic and treatment options such as echocardiography and inhaled nitric oxide (iNO) are not routinely available in resource limited settings and alternative treatment modalities need to be utilized. This study was conducted to assess current diagnostic and management strategies used for PPHN in Indian neonatal intensive care units (NICUs).
A questionnaire in multiple choice question format was sent to practising neonatologists in India via an online survey tool between July to August 2021. Information pertaining to demographic data, diagnostic criteria and management strategies of PPHN was requested. The responses were collated and information processed.
There were 118 respondent NICUs (response rate 74%). The majority of neonatal units (65%) admitted an average of 1-3 patients of PPHN per month. Targeted neonatal echocardiography (TnECHO) was practised in 80% of the units. Most common management strategies being followed were pulmonary vasodilators (88.1%), inotropes (85.6%), conventional ventilation (68.6%) and high frequency ventilation (59.3%). The most preferred pulmonary vasodilator was sildenafil (79%) and inotropic agent was milrinone (32%). Only 25% of respondents reported use of iNO. None of the participating units used extracorporeal membrane oxygenation.
We found wide variability in management practices of PPHN across Indian NICUs. Non-selective pulmonary vasodilators are more widely used than iNO. There is an urgent need for structured TnECHO training programs and evidence based national guidelines for standardized management of PPHN as per availability of resources in India. Additional research on low cost alternative therapies to iNO in Indian settings might be helpful.
新生儿持续性肺动脉高压(PPHN)是一种常见的新生儿疾病,与较高的发病率和死亡率相关。在资源有限的环境中,无法常规使用超声心动图和吸入一氧化氮(iNO)等一线诊断和治疗选择,因此需要利用替代治疗方法。本研究旨在评估印度新生儿重症监护病房(NICU)中 PPHN 的现行诊断和管理策略。
我们通过在线调查工具于 2021 年 7 月至 8 月向印度的执业新生儿科医生发送了一份多项选择题形式的问卷,以获取有关 PPHN 的人口统计学数据、诊断标准和管理策略的信息。我们对回复进行了整理和信息处理。
共有 118 家回复的 NICU(回复率为 74%)。大多数新生儿病房(65%)平均每月收治 1-3 例 PPHN 患者。80%的单位进行了有针对性的新生儿超声心动图(TnECHO)检查。最常遵循的管理策略是肺血管扩张剂(88.1%)、正性肌力药(85.6%)、常规通气(68.6%)和高频通气(59.3%)。最常使用的肺血管扩张剂是西地那非(79%),正性肌力药物是米力农(32%)。只有 25%的受访者报告使用 iNO。参与的单位均未使用体外膜氧合。
我们发现印度的 NICU 之间在 PPHN 管理实践方面存在广泛差异。非选择性肺血管扩张剂的使用比 iNO 更为广泛。印度需要根据当地资源情况,紧急制定结构化的 TnECHO 培训计划和基于证据的国家指南,以标准化 PPHN 的管理。在印度环境中,对 iNO 的低成本替代疗法进行额外研究可能会有所帮助。